Adma Biologics raises FY25 revenue view to at least $510M from at least $500M

Consensus $506.28M. Backs FY25 adjusted EBITDA view $235M. The company said, “In parallel, we continue to work towards operational efficiency and a disciplined capital deployment strategy. Supported by a strong balance sheet, robust forecasted cash generation, continued advancement of our SG-001 pipeline program and organically funded share repurchases, we believe ADMA is well-positioned to deliver accelerating earnings growth, expanding margins, and stockholder value creation.”